Dimethyl Fumarate: Use in Psoriasis

Overview / Definition Dimethyl fumarate (DMF) is a fumaric acid ester that is primarily used in the treatment of psoriasis and multiple sclerosis. In dermatology, it is indicated for the management of moderate to severe plaque psoriasis, particularly in patients who are candidates for systemic therapy. DMF is known for its immunomodulatory properties, which help in reducing the inflammatory response seen in psoriasis. Epidemiology Psoriasis affects approximately 2-3% of the global population, with a higher prevalence in Caucasians. The onset typically occurs in young adulthood, with peaks in incidence at the ages of 20-30 years and 50-60 years. DMF is often considered for patients who have not responded adequately to topical therapies or phototherapy. Common demographic: Adults aged 20-30 and 50-60. Prevalence is higher in Caucasian populations. Consider DMF in patients with moderate to severe psoriasis. Pathophysiology / Mechanism The precise mechanism of action of DMF in psoriasis is not fully understood. However, it is believed to exert its effects through several pathways: Immunomodulation: DMF reduces the activation of T cells and inhibits the production of pro-inflammatory cytokines. Antioxidant effects: It has potent antioxidant properties, which may help in reducing oxidative stress associated with psoriasis. Inhibition of NF-kB: DMF may inhibit nuclear factor kappa B (NF-kB), a transcription factor that plays a key role in inflammation. Clinical Presentation Patients with psoriasis typically present with: Raised, erythematous plaques covered with silvery scales. Itching, burning, or discomfort in affected areas. Common sites include the scalp, elbows, knees, and lower back. Nail involvement may occur, with pitting and onycholysis. Diagnosis / Workup The diagnosis of psoriasis is primarily clinical, based on the characteristic appearance of the skin lesions: Consider a skin biopsy if the diagnosis is uncertain or when considering differential diagnoses such